Testing BL-M11D1 for advanced AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called BL-M11D1 for people with a type of leukemia that has come back or not responded to standard treatments. It aims to see if the drug is safe and works against cancer cells that have a protein called CD33.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have acute myeloid leukemia (AML) that has CD33 protein and has returned or not responded to treatment.
- You need to be at least 18 years old and have a life expectancy of 3 months or more.
- You should be well enough to do daily activities (ECOG score 0-2).
- Your liver and kidneys must work well enough based on blood tests.
- You must not have certain heart conditions, active infections, or other serious medical issues.
- If you could become pregnant, you need to use effective birth control and not be breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral investigational drug (GLB-001) for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has returned or hasn't responded to other treatments. The goal is to see if it's safe and effective for those who have run out of standard options.
This Phase 1 trial tests BL-M11D1, a drug designed to target CD33 found on certain AML cells, in adults whose AML has come back or is hard to treat. If you qualify, you may be offered early access to a potential new option while researchers closely monitor safety and side effects.
This trial tests a new antibody-based drug called BL-M11D1 in patients whose myelodysplastic syndrome (a blood disorder where the bone marrow doesn't make healthy blood cells) has come back or stopped responding to previous treatments. The drug targets CD33, a protein on certain blood cells, to help the immune system fight the disease.
This study tests a new drug called BL-M11D1 combined with standard chemotherapy (cytarabine + daunorubicin) or a targeted therapy (venetoclax + azacitidine) for people with newly diagnosed acute myeloid leukemia (AML). It aims to see if this combination is safe and effective.
This trial tests a new drug called BL-M08D1 for people with lymphoma or other blood cancers that came back or didn't respond to standard treatments. It aims to see if the drug can help when other options are no longer working.
This trial tests a new drug called CG009301 for people with blood cancers that have come back or haven't responded to standard treatments. The goal is to see if the drug is safe and works against these cancers.
Hear when a new Relapsed/Refractory Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.